CAC Testing Positioned as Targeted Decision Aid, Not Universal Screening Tool

The American Heart Association clarifies that coronary artery calcium testing is best used as a targeted decision aid for people at borderline or intermediate cardiovascular risk, not as a routine screening test for everyone.

Chicago Metrowire Staff
••Healthcare
CAC Testing Positioned as Targeted Decision Aid, Not Universal Screening Tool

The American Heart Association is drawing a clear line between appropriate and inappropriate use of coronary artery calcium (CAC) testing, a quick, noninvasive CT scan that detects calcium deposits in the coronary arteries—an early sign of plaque buildup, or atherosclerosis. The distinction matters because recent research and media coverage have blurred the test’s role, potentially prompting consumers to seek scans they do not need while overlooking the people who could benefit most.

According to the American Heart Association/American College of Cardiology dyslipidemia guideline, CAC scoring is supported for selective use, particularly when a person’s cardiovascular risk falls in a middle range and there is uncertainty about whether to begin or intensify cholesterol-lowering treatment. The 2026 guideline encourages clinicians to start with the American Heart Association’s PREVENT™ equations to estimate risk and then use CAC as a refinement tool when the answer remains unclear. “The American Heart Association does not recommend broad based use of the CAC test for screening. The Association recommends it as a decision aid for people at borderline or intermediate risk … It is a tiebreaker test,” said Manesh R. Patel, M.D., FAHA, volunteer president of the American Heart Association and chief of the division of cardiology at Duke University School of Medicine.

The implications for patients and clinicians are significant. For many people, modern risk estimation with PREVENT can identify coronary artery disease risk effectively without additional testing. Adding CAC information is particularly useful for those in borderline (3% to less than 5%) and intermediate (5% to less than 10%) risk groups, where the result can change the decision about whether to start a statin. The scan, which typically costs $100 to $400 and is often not covered by insurance, provides the greatest value when it alters a treatment decision—not when risk is already very low or when the appropriate treatment is already clear, such as for people with diabetes or very high cholesterol. It is also generally not helpful for those who have already had a heart attack or cardiac catheterization.

Consumers should understand that a CAC score of zero is reassuring but not a lifetime “all clear.” It does not rule out noncalcified plaque, and other factors such as diabetes, smoking, very high cholesterol and a strong family history of premature heart disease still matter. The Association emphasizes that the first prescription for prevention should be lifestyle modification, including avoiding tobacco and emphasizing healthy diet, exercise and sleep as defined by Life’s Essential 8. Individuals can use the Life's Essential 8™ My Life Check Calculator to learn their own heart health score at home and prepare for a conversation with their healthcare team.

For those who want to learn more, the Association offers detailed information on coronary artery calcium testing (CAC test) from the American Heart Association, including who may benefit and what to expect during the scan. The Association’s national initiative, Catalyzing CAC Testing to Transform Heart Health, further supports appropriate use of the test. Additional resources include the About the PREVENT™ Equations page and the 2026 ACC/American Heart Association cholesterol guideline news release.

Blockchain Registration

QR Code for Blockchain Registration